Table 1. Baseline Characteristics.

Source	Age, mean, y		Sex, % male		Country
Source	Intervention	Control	Intervention	Control	Country
Shakur et al,² 2010	34.6	34.5	83.6	84.0	40 countries worldwide
Guyette et al,³ 2020	41	42	73.2	74.8	US
Rowell et al,⁴ 2020	39^a	36^a	73	75	US and Canada
CRASH-3 trial collaborators,¹³ 2019	41.7	41.9	80	80	29 countries worldwide
Chakroun-Walha et al,¹⁴ 2019	44	39	57	57	Tunisia
Yutthakasemsunt et al,¹⁵ 2013	34.8	34.1	86	91	Thailand
Bardes et al,¹⁶ 2017	NR	NR	NR	NR	US
Boutonnet et al,¹⁷ 2018	42	42	73.6	73.1	France
Chan et al,¹⁸ 2019	66.4	66.4	62.9	62.9	China
Cole et al,¹⁹ 2015	42	40	78	82	UK
Dixon et al,²⁰ 2019	41	42	47	43	US
El-Menyar et al,²¹ 2020	31.4	31.5	96.1	89.2	Qatar
Glover et al,²² 2019	45.3	51.9	75.7	72.1	UK
Harvin et al,²³ 2015	37	32	80	74	US
Howard et al,²⁴ 2017	24.6	24.9	97.1	95.4	US
Johnston et al,²⁵ 2018	25.3	27.4	99.3	96.4	US
Khan et al,²⁶ 2018	42.5	38.7	66	68	US
Lewis et al,²⁷ 2016	24.2	24.2	90.7	91.1	US
Luehr et al,²⁸ 2017	41.6	41.9	42	36	US
Moore et al,²⁹ 2017	27	34	85	77	US
Morrison et al,³⁰ 2012	23.8	22.9	98.4	96.9	UK
Morrison et al,³¹ 2013	24.2	23.6	96.6	93.7	UK
Morte et al,³² 2019	24.7	25.3	100	100	US
Myers et al,³³ 2019	36	32	75	70	US
Neeki et al,³⁴ 2018	38	37.6	80.9	80.9	US
Neeki et al,³⁵ 2020	38.9	37.9	84.3	86.1	US
Shiraishi et al,³⁶ 2017	57^a	56^a	72.4	74.4	Japan
Swendsen et al,³⁷ 2013	44.6	47.6	37	49	US
Valle et al,³⁸ 2014	42	43	85	86	US
Wafaisade et al,³⁹ 2016	43	41	72.5	72.5	Germany
Walker et al,⁴⁰ 2020	24.2	25.5	NR	NR	US

Abbreviations: CRASH-3, Clinical Randomisation of an Antifibrinolytic in Significant Head Injury; NR, not reported.

^{^a}

Expressed as median.